Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial

Name: Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
Published: 2026
License: Public Domain

The First Affiliated Hospital with Nanjing Medical University · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

gc/gejc, adjuvant therapy, gastric adenocarcinom, rc48, sox, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial

Related documents